Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences Inc (NASDAQ: PLSE) pioneers bioelectric medicine through its proprietary Nano-Pulse Stimulation technology, offering investors and medical professionals a novel approach to non-thermal therapies. This dedicated news hub provides real-time updates on clinical advancements, regulatory developments, and strategic partnerships shaping the future of targeted cellular treatments.
Access verified information about PLSE's progress in immuno-oncology applications, dermatology research breakthroughs, and system commercialization efforts. Our curated feed includes earnings reports, FDA submissions, peer-reviewed study results, and executive commentary – all essential for evaluating the company's position in the electroceuticals market.
Key updates cover therapeutic trial milestones, intellectual property expansions, and collaborations with leading medical institutions. Bookmark this page to monitor how PLSE's drug-free energy modalities could transform treatment protocols for complex conditions while driving long-term value in the medical device sector.
Pulse Biosciences (Nasdaq: PLSE) announced that late‑breaking data from its nPulse Cardiac Catheter Ablation System first‑in‑human feasibility study in Europe was accepted for presentation at the 31st Annual AF Symposium 2026 in February.
The presentation, by Vivek Reddy, MD, will include 6‑month and 12‑month follow‑up data from the study. The company said it will provide presentation times in late January.
Pulse Biosciences (Nasdaq: PLSE) will present at the 44th Annual J.P. Morgan 2026 Healthcare Conference in San Francisco. Management is scheduled to present on Wednesday, January 14, 2026 at 3:45pm PT. A live and recorded webcast will be available on the company’s investor website under the Events Calendar and Presentations page. The company leverages its nPulse™ platform using Nanosecond Pulsed Field Ablation™ (nsPFA™) energy.
Pulse Biosciences (Nasdaq: PLSE) announced that its Compensation Committee approved inducement equity awards to two new employees on December 15, 2025 under the 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards grant options to purchase an aggregate of 3,400 shares at an exercise price of $14.13 per share (equal to the closing price on December 15, 2025). Options vest on a four-year, time-based schedule with 1/4 vesting annually, subject to continued employment, and are governed by the inducement plan and award agreements.
Pulse Biosciences (Nasdaq: PLSE) announced the U.S. Food and Drug Administration has granted an IDE to start the NANOPULSE-AF study evaluating its nPulse Cardiac Catheter Ablation System for treatment of paroxysmal atrial fibrillation.
The single-arm, multicenter, prospective study plans up to 30 sites (including three outside the U.S.) and up to 145 patients (ClinicalTrials.gov NCT07018596). Pulse noted an ongoing European feasibility study has enrolled 150 patients with follow-up ongoing. The nPulse system uses nanosecond pulsed field ablation (nsPFA) and is designed to deliver a complete circumferential lesion in a single brief application, aiming to lower total energy and reduce collateral injury.
Pulse Biosciences (Nasdaq: PLSE) announced a research collaboration with MD Anderson to study its nPulse™ Vybrance™ Percutaneous Electrode System for benign and malignant thyroid tumors.
An FDA Investigational Device Exemption (IDE) for a first-in-human feasibility study was approved. The two-site trial is planned to begin early 2026 and enroll 30 subjects to evaluate safety and effectiveness for papillary thyroid microcarcinoma. Preclinical work with MD Anderson on anaplastic thyroid carcinoma is ongoing.
Pulse Biosciences (Nasdaq: PLSE) announced inducement equity awards approved November 18, 2025 under its 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Compensation Committee granted options to three new employees to purchase an aggregate of 13,450 shares of common stock.
The options carry an exercise price of $13.58 per share (equal to the closing price on November 18, 2025) and vest on a time-based four-year schedule with 1/4 vesting annually, subject to continued employment and the award agreements.
Pulse Biosciences (Nasdaq: PLSE) will present at two investor conferences in New York in November–December 2025. Management is scheduled to speak at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 2:40 PM ET and at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:50 AM ET. Live and recorded webcasts will be available on the company investor website at http://investors.pulsebiosciences.com/.
Pulse Biosciences (Nasdaq: PLSE) reported Q3 2025 business updates and financial results for the quarter ended September 30, 2025. Key clinical milestones include FDA IDE approval and initial enrollment in the nPulse Cardiac Surgery System surgical AF study (NANOCLAMP AF), PRECISE-BTN study 40% enrolled for benign thyroid nodules, and submission/planned IDE start for the endocardial nPulse 360° catheter in Q1 2026. The company has treated over 200 patients across programs and generated $86 thousand revenue from limited market release.
Q3 GAAP costs and expenses were $20.5M (GAAP net loss $19.4M); non-GAAP loss was $13.5M. Cash and equivalents were $95.2M at September 30, 2025.
Pulse Biosciences (Nasdaq: PLSE) announced first U.S. patient enrollment in the NANOCLAMP AF Study on October 24, 2025, using the nPulse Cardiac Surgical System after receiving FDA IDE approval.
The single-arm, prospective multicenter study will evaluate safety and effectiveness of the nsPFA-driven nPulse Cardiac Clamp for atrial fibrillation during concomitant surgical procedures, with multiple U.S. and two international sites planned. The device holds FDA Breakthrough Device designation (July 2024) and is in the FDA TPLC Advisory Program.
Pulse Biosciences (Nasdaq: PLSE) will report third quarter 2025 business updates and financial results after market close on Wednesday, November 5, 2025.
Company management will host a conference call on November 5, 2025 at 1:30 PM PT / 4:30 PM ET. U.S. dial-in is 1-800-715-9871; international dial-in is 1-646-307-1963; use Conference ID 7706791. A live and recorded webcast will be available on the Pulse Biosciences investors website at http://investors.pulsebiosciences.com/.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
